Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 2 Mar 2026

Ramelyte Egle, Kött Julian, Lawless Aleigha R, Ciernik Amélie, Heidrich Isabel, Zellweger Caroline, Montazeri Kamaneh, Mangana Joanna, Smit Daniel J, Freiberger Sandra N, Orjuela Stephany, Dummer Reinhard, Sullivan Ryan J, Levesque Mitchell P, Gebhardt Christoffer

Abstract excerpt

PURPOSE: Circulating tumor DNA (ctDNA) refers to small DNA fragments, shed from tumor cells into the bloodstream. Measuring ctDNA provides a noninvasive tool for real-time disease monitoring. Although ctDNA predicted overall survival (OS) in metastatic uveal melanoma (mUM) treated with tebentafusp, its broader prognostic value across treatment modalities remains unclear. In this study, we assess the prognostic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Neoplasm Metastasis

Share to Prognosis

Share to Treatment Outcome

Share to Uveal Melanoma

Share to Uveal Neoplasms

Source

Identifiers

PMID: 41385580
DOI: 10.1158/1078-0432.CCR-25-2274

Genes

MAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma.PMID 41385580Read ↗

Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafuspSemantic proximity Read ↗

Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.Semantic proximity Read ↗

Release of Cell-Free Tumor DNA in the Plasma of Uveal Melanoma Patients Under Radiotherapy.Semantic proximity Read ↗

In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibitionSemantic proximity Read ↗

Presence of tumor DNA in aqueous humor is correlated with high risk uveal melanomaSemantic proximity Read ↗

Development of a Nomogram to Predict Therapeutic Resistance in Metastatic Melanoma Using Longitudinal ctDNA Kinetics.Semantic proximity Read ↗

Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma.Semantic proximity Read ↗

Early detection of metastatic uveal melanoma by the analysis of tumor-specific mutations in cell-free plasma DNA.Semantic proximity Read ↗

Circulating Tumor DNA as a Prognostic Factor in Patients With Resectable Hepatic Metastases of Uveal Melanoma.Semantic proximity Read ↗

Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic MelanomaSemantic proximity Read ↗

Circulating Tumor DNA in Conjunctival Melanoma: Landscape and Surveillance Value.Semantic proximity Read ↗

Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.